Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432391 · ClinicalTrials.gov registry record · NA
Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations
A NA study, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT02432391: Completed NA study, sponsored by University of Virginia.
NCT02432391 is a NA study that has completed, run by University of Virginia. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02432391, a NA study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a lifestyle modification program (GEM) that focuses on reducing after-meal blood glucose elevations can improve blood glucose control in people with type 2 diabetes. Half of the participants will continue their routine medical care, and half will receive five sessions of GEM in addition to their routine care. The two groups will be assessed using diabetes-relevant medical, behavioral and psychological measures.
Primary Outcome
HbA1c
Interventions
- BEHAVIORAL GEM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-01 |
| Phase | NA |
What the finished NCT02432391 record still lists
NCT02432391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which GEM is the first listed.
NCT02432391 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02432391 about?
NCT02432391 is a clinical study titled "Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations". The purpose of this study is to determine if a lifestyle modification program (GEM) that focuses on reducing after-meal blood glucose elevations can improve blood glucose control in people with type 2 diabetes. Half of the participants will continue their routine medical care, and half will receive ...
What is the current status of trial NCT02432391?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2013-05. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02432391?
The interventions under investigation include: GEM (BEHAVIORAL).
Who is sponsoring clinical trial NCT02432391?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02432391's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia